• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    FDA Efforts To Curb Flavored Vapes Said To Draw Supreme Court Review

    7/2/24 9:32:09 AM ET
    $MO
    $PM
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $MO alert in real time by email

    - Bloomberg

    Get the next $MO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MO
    $PM
    $XXII

    CompanyDatePrice TargetRatingAnalyst
    Philip Morris International Inc
    $PM
    1/20/2026$180.00Buy → Hold
    Jefferies
    Altria Group Inc.
    $MO
    1/9/2026$63.00Neutral → Buy
    UBS
    Philip Morris International Inc
    $PM
    7/9/2025$220.00Buy
    Jefferies
    Altria Group Inc.
    $MO
    7/9/2025$50.00Underperform
    Jefferies
    Altria Group Inc.
    $MO
    7/2/2025$59.00Sell → Neutral
    UBS
    Philip Morris International Inc
    $PM
    5/22/2025$195.00Buy
    Needham
    Philip Morris International Inc
    $PM
    4/25/2025$170.00Sell → Neutral
    UBS
    Altria Group Inc.
    $MO
    4/1/2025Buy → Hold
    Deutsche Bank
    More analyst ratings

    $MO
    $PM
    $XXII
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Philip Morris International downgraded by Jefferies with a new price target

    Jefferies downgraded Philip Morris International from Buy to Hold and set a new price target of $180.00

    1/20/26 9:10:49 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria upgraded by UBS with a new price target

    UBS upgraded Altria from Neutral to Buy and set a new price target of $63.00

    1/9/26 8:23:08 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Jefferies resumed coverage on Philip Morris International with a new price target

    Jefferies resumed coverage of Philip Morris International with a rating of Buy and set a new price target of $220.00

    7/9/25 8:31:10 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $MO
    $PM
    $XXII
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Philip Morris International Presents its Value Report 2025: change in motion

    The company's annual disclosure unveils its Value Plan 2030+ Philip Morris International (NYSE:PM) today released its Value Report 2025, offering a holistic perspective on the company's approach to sustainable value creation. The report marks the completion of PMI's 2025 Roadmap, communicating achievements for each aspiration introduced by the company in 2020, and introduces its Value Plan 2030+, set to guide the company's continued path to sustainable growth. "For more than a decade, PMI has pursued an industry-leading shift away from cigarettes—a transformation that goes far beyond product innovation to encompass how we allocate capital, engage stakeholders, and measure success," said

    3/31/26 4:30:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    PMI U.S. BRINGS TECHNOVATION TO WASHINGTON D.C.

    PMI's global science and innovation platform brings together leaders to accelerate progress toward a smoke-free futureWASHINGTON, March 30, 2026 /PRNewswire/ -- Technovation, the global science and innovation platform of Philip Morris International (PMI) (NYSE:PM), will make its U.S. debut on April 14. The one-day event brings together experts, policymakers, scientists, media, and business leaders across the Americas to explore how innovation, science, and regulation can accelerate progress toward a smoke-free future. The U.S. launch of Technovation marks a key moment for the pl

    3/30/26 8:00:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    22nd Century Group Reports Fourth Quarter and Full Year 2025 Financial Results

    VLN® Commercial Expansion Drives Continued Shift Toward Higher Margin Proprietary Branded Products Expanding VLN® Store Counts and State Authorizations Increase Availability of Smoking Harm Reduction Products MOCKSVILLE, N.C., March 26, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company focused on reducing the harms of smoking through nicotine reduction, today announced results for the fourth quarter and fiscal year-ended December 31, 2025, and provided an update on recent business highlights. The Company's proprietary low nicotine technology is designed to serve adult smokers who want to change their smoking habits by significantly reduci

    3/26/26 6:00:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $MO
    $PM
    $XXII
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    December 23, 2021 - FDA Authorizes Marketing of Tobacco Products that Help Reduce Exposure to and Consumption of Nicotine for Smokers Who Use Them

    For Immediate Release: December 23, 2021 Today, the U.S. Food and Drug Administration authorized the marketing of 22nd Century Group Inc.’s “VLN King” and “VLN Menthol King” combusted, filtered cigarettes as modified risk tobacco products (MRTPs), which help reduce exposure to, and consumption of, nicotine for smokers who use them. These are the first combusted cigarettes to be authorized as MRTPs and the second

    12/23/21 9:06:12 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $MO
    $PM
    $XXII
    SEC Filings

    View All

    SEC Form DEFA14A filed by Altria Group Inc.

    DEFA14A - ALTRIA GROUP, INC. (0000764180) (Filer)

    4/2/26 9:02:06 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form DEF 14A filed by Altria Group Inc.

    DEF 14A - ALTRIA GROUP, INC. (0000764180) (Filer)

    4/2/26 9:00:30 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form S-3 filed by 22nd Century Group Inc.

    S-3 - 22nd Century Group, Inc. (0001347858) (Filer)

    3/31/26 5:00:54 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $MO
    $PM
    $XXII
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Firestone Lawrence bought $10,468 worth of shares (39,000 units at $0.27), increasing direct ownership by 256% to 54,250 units (SEC Form 4)

    4 - 22nd Century Group, Inc. (0001347858) (Issuer)

    9/12/24 5:00:14 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    Firestone Lawrence bought $9,829 worth of shares (9,000 units at $1.09), increasing direct ownership by 144% to 15,250 units (SEC Form 4)

    4 - 22nd Century Group, Inc. (0001347858) (Issuer)

    5/31/24 4:05:20 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    Arno Andrew bought $17,490 worth of shares (100,000 units at $0.17) (SEC Form 4)

    4 - 22nd Century Group, Inc. (0001347858) (Issuer)

    1/8/24 8:04:11 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $MO
    $PM
    $XXII
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Group Controller Dobrowolski Reginaldo covered exercise/tax liability with 22 shares (SEC Form 4)

    4 - Philip Morris International Inc. (0001413329) (Issuer)

    3/9/26 4:23:03 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    SVP, Chief HR Off. & CCO Whitaker Charles N. sold $1,885,718 worth of shares (27,908 units at $67.57), decreasing direct ownership by 13% to 180,869 units (SEC Form 4)

    4 - ALTRIA GROUP, INC. (0000764180) (Issuer)

    3/9/26 2:38:41 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    EVP & General Counsel Mccarter Robert A. Iii was granted 5,767 shares and covered exercise/tax liability with 4,517 shares, increasing direct ownership by 1% to 123,612 units (SEC Form 4)

    4 - ALTRIA GROUP, INC. (0000764180) (Issuer)

    3/2/26 3:47:47 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    $MO
    $PM
    $XXII
    Financials

    Live finance-specific insights

    View All

    22nd Century Group Reports Fourth Quarter and Full Year 2025 Financial Results

    VLN® Commercial Expansion Drives Continued Shift Toward Higher Margin Proprietary Branded Products Expanding VLN® Store Counts and State Authorizations Increase Availability of Smoking Harm Reduction Products MOCKSVILLE, N.C., March 26, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company focused on reducing the harms of smoking through nicotine reduction, today announced results for the fourth quarter and fiscal year-ended December 31, 2025, and provided an update on recent business highlights. The Company's proprietary low nicotine technology is designed to serve adult smokers who want to change their smoking habits by significantly reduci

    3/26/26 6:00:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International Declares Regular Quarterly Dividend of $1.47 Per Share

    Regulatory News: The Board of Directors of Philip Morris International Inc. (NYSE:PM) today declared a regular quarterly dividend of $1.47 per common share, payable on April 13, 2026, to shareholders of record as of March 19, 2026. The ex-dividend date is March 19, 2026. For more details on stock, dividends and other information, see www.pmi.com/dividend. Philip Morris International: A Global Smoke-Free Champion Philip Morris International is a leading international consumer goods company, actively delivering a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company's current product portfolio primarily

    3/5/26 7:00:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria Declares Regular Quarterly Dividend of $1.06 Per Share

    Altria Group, Inc. (NYSE:MO) today announced that our Board of Directors declared a regular quarterly dividend of $1.06 per share, payable on April 30, 2026 to shareholders of record as of March 25, 2026. The ex-dividend date is March 25, 2026. View source version on businesswire.com: https://www.businesswire.com/news/home/20260225648687/en/ Altria Client Services Investor Relations 804-484-8222 Altria Client Services Media Relations 804-484-8897 www.altria.com/contact-us/media

    2/26/26 1:00:00 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    $MO
    $PM
    $XXII
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by 22nd Century Group Inc.

    SC 13G/A - 22nd Century Group, Inc. (0001347858) (Subject)

    12/3/24 11:18:54 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form SC 13G/A filed by 22nd Century Group Inc.

    SC 13G/A - 22nd Century Group, Inc. (0001347858) (Subject)

    11/14/24 5:56:57 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G filed by 22nd Century Group Inc.

    SC 13G - 22nd Century Group, Inc. (0001347858) (Subject)

    10/23/24 7:27:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $MO
    $PM
    $XXII
    Leadership Updates

    Live Leadership Updates

    View All

    Philip Morris International Opens Dialogue on the Future of Human Cognition as a Defining Frontier in the Age of AI

    The paper calls for global debate to ensure AI enhances—rather than diminishes—uniquely human strengths in an increasingly automated world Philip Morris International Inc. (NYSE:PM) today released a new white paper, "Human Cognition: The Next Frontier?", inviting leaders across business, policy, and academia to join a global conversation on the evolving role of human cognition as artificial intelligence transforms work, society, and the economy. The white paper explores how human capabilities such as - critical thinking, creativity and adaptability - are poised to become the "superskill" of the future, driving progress in an era of human-machine collaboration. As AI automates routine ta

    1/20/26 5:03:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria Group, Inc. Announces Retirement of CEO Billy Gifford and Appointment of Sal Mancuso as Successor

    Altria Group, Inc. (Altria) (NYSE:MO) announces today that Billy Gifford, Altria's Chief Executive Officer (CEO), has decided to retire, effective May 14, 2026 at the conclusion of the 2026 Annual Meeting of Shareholders (2026 Annual Meeting). Billy has had a distinguished career of over 30 years with the Altria family of companies and has served as Altria's CEO since 2020. Altria's Board of Directors (Board) has elected Salvatore (Sal) Mancuso to serve as Altria's CEO upon Billy's retirement. To facilitate a smooth transition, Billy plans to serve as a consultant to Altria upon his retirement through at least the end of 2026. Additionally, the Board elected Heather Newman to serve as Altri

    12/11/25 7:00:00 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria Group, Inc. Announces Retirement of Director George Muñoz from Board of Directors

    Altria Group, Inc. (Altria) (NYSE:MO) -- George Muñoz, a director of Altria since 2004, notified Altria of his decision to retire from service on our Board of Directors (Board) following the completion of his current term. Consequently, Mr. Muñoz will not stand for re-election to our Board at our 2026 Annual Meeting of Shareholders, which Altria anticipates holding on May 14, 2026. "George has made extensive and significant contributions to Altria over more than 20 years," said Kathryn McQuade, Altria's independent Chair of the Board. "We thank George for his long-standing and valuable service and wish him the very best upon his retirement." Mr. Muñoz is Chair of the Compensation and Ta

    10/9/25 8:35:00 AM ET
    $LAUR
    $MO
    Other Consumer Services
    Real Estate
    Medicinal Chemicals and Botanical Products
    Health Care